匹伐他汀治疗高血压合并冠心病的效果
|
摘要
目的探讨匹伐他汀治疗高血压合并冠心病的效果。方法选取2016年8月～2017年11月我院确诊的126例高血压合并冠心病的患者作为研究对象,将患者按照入院编号随机分为实验组和对照组,每组各63例。实验组给予匹伐他汀,对照组给予辛伐他汀,连续治疗8周,测定患者血脂[血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]及血压水平,丙氨酶氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、肌酸磷酸激酶(CPK)水平,观察患者生命体征变化及不良反应。结果服药前两组血脂与血压水平比较,差异无统计学意义(P>0.05);服药后两组的血脂与血压水平比较,差异无统计学意义(P>0.05);治疗后实验组与对照组血脂与血压水平均低于治疗前,差异有统计学意义(P<0.05)。治疗前两组的ALT、AST、CPK指标比较,差异无统计学意义(P>0.05);治疗后实验组ALT、AST、CPK指标均低于对照组,差异有统计学意义(P<0.05);治疗后两组的ALT、AST、CPK指标均低于治疗前,差异有统计学意义(P<0.05)。结论匹伐他汀具有较强的降脂作用,对收缩压的降低作用比舒张压明显,值得在临床推广使用。
Objective To evaluate the effect of Pivastatin in the treatment of hypertension with coronary heart disease.Methods From August 2016 to November 2017, 126 patients with hypertension and coronary heart disease were selected. According to the hospital number, the patients were randomly divided into experimental group and control group, 63 cases in each group. The experimental group was given Pivastatin, while the control group was given simvastatin for 8 weeks. The blood lipid [serum total cholesterol(TC), triglyceride(TG), high density lipoprotein cholesterol(HDL-C)] were measured, low density lipoprotein cholesterol(LDL-C) and blood pressure, alanine aminotransferase(ALT), aspartate aminotransferase(AST), creatine phosphokinase(CPK). The changes of vital signs and adverse reactions were observed and the data were statistically analyzed. Results There was no significant difference in blood lipid and blood pressure between the two groups before taking medicine(P>0.05), but there was no significant difference between the two groups after taking medicine(P >0.05). The levels of blood lipid and blood pressure in experimental group and control group were significantly lower than those before treatment(P<0.05). There was no significant difference in ALT, AST, CPK between the two groups before treatment(P>0.05), but the ALT, AST, CPK index of the experimental group was lower than that of the control group(P<0.05). The ALT, AST, CPK indexes of the control group and the experimental group were lower than those of the control group after treatment, and the differences were statistically significant(P<0.05). Conclusion Pivastatin has a strong lipid-lowering effect, and its effect on systolic blood pressure is more obvious than that on diastolic blood pressure, so it is worth popularizing in clinic.
Objective To evaluate the effect of Pivastatin in the treatment of hypertension with coronary heart disease.Methods From August 2016 to November 2017, 126 patients with hypertension and coronary heart disease were selected. According to the hospital number, the patients were randomly divided into experimental group and control group, 63 cases in each group. The experimental group was given Pivastatin, while the control group was given simvastatin for 8 weeks. The blood lipid [serum total cholesterol(TC), triglyceride(TG), high density lipoprotein cholesterol(HDL-C)] were measured, low density lipoprotein cholesterol(LDL-C) and blood pressure, alanine aminotransferase(ALT), aspartate aminotransferase(AST), creatine phosphokinase(CPK). The changes of vital signs and adverse reactions were observed and the data were statistically analyzed. Results There was no significant difference in blood lipid and blood pressure between the two groups before taking medicine(P>0.05), but there was no significant difference between the two groups after taking medicine(P >0.05). The levels of blood lipid and blood pressure in experimental group and control group were significantly lower than those before treatment(P<0.05). There was no significant difference in ALT, AST, CPK between the two groups before treatment(P>0.05), but the ALT, AST, CPK index of the experimental group was lower than that of the control group(P<0.05). The ALT, AST, CPK indexes of the control group and the experimental group were lower than those of the control group after treatment, and the differences were statistically significant(P<0.05). Conclusion Pivastatin has a strong lipid-lowering effect, and its effect on systolic blood pressure is more obvious than that on diastolic blood pressure, so it is worth popularizing in clinic.
引文
[1]林坚.中西医结合治疗糖心病合并心包积液1例[J].广东医学,2016,37(Z1):240-240.
[2]李耀荣.血府逐瘀汤联合阿托伐他汀治疗高血压并发冠心病临床疗效[J].天津药学,2017,29(3):46-47.
[3]范瑞云,石磊,董均杰,等.不同他汀对绝经后高血压血脂异常合并糖耐量减低患者的疗效观察[J].解放军预防医学杂志,2017,35(6):571-574.
[4]黄国锋,谭清容,龙燕玲,等.匹伐他汀钙片治疗老年原发性高血压病合并高脂血症的疗效观察[J].华夏医学,2017,30(4):4-7.
[5]吴彦.阿托伐他汀对高血压患者颈动脉斑块的疗效观察[J].浙江临床医学,2016,18(8):1393-1395.
[6]刘金发,林杰.匹伐他汀钙联合依折麦布治疗冠心病合并高脂血症的疗效及安全性观察[J].解放军预防医学杂志,2018,36(9):1114-1117.
[7]温灵武,高伟青,刘菁,等.对比阿托伐他汀与瑞舒伐他汀在冠心病治疗中的应用价值[J].北方药学,2018,15(6):21-22.
[8]赵宏伟,孙磊,于倩,等.匹伐他汀和辛伐他汀治疗不稳定性心绞痛的效果及安全性比较[J].中国当代医药,2014,21(7):74-76.
[9]徐小明,罗兴迪,杨靓靓,等.阿托伐他汀钙片联合心血管药物治疗冠心病的临床研究[J].重庆医学,2016,45(19):2701-2702.
[10]李莉.瑞舒伐他汀与阿托伐他汀在冠心病调脂治疗中的药物经济学比较[J].海峡药学,2015,27(10):271-273.
[11]陈丽琴.分析不同他汀类药物(瑞舒伐他汀、阿托伐他汀)调脂效果及使用依从性[J].北方药学,2017,14(12):147-147.
[12]安素,张明.不同剂量普伐他汀对冠心病患者血脂与血清胱抑素C的影响及意义[J].海南医学院学报,2015,21(3):362-365.
[13]佀瑞淑.阿托伐他汀钙联合阿司匹林对冠心病患者血脂及炎性因子水平的影响[J].四川生理科学杂志,2018,40(2):109-111.
[14]周冠增.阿托伐他汀钙联合阿司匹林对冠心病患者血脂及炎性因子水平的影响[J].淮海医药,2018,36(3):350-352.
[15]于楠.氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果观察[J].中国当代医药,2015,22(24):49-50,53.
[2]李耀荣.血府逐瘀汤联合阿托伐他汀治疗高血压并发冠心病临床疗效[J].天津药学,2017,29(3):46-47.
[3]范瑞云,石磊,董均杰,等.不同他汀对绝经后高血压血脂异常合并糖耐量减低患者的疗效观察[J].解放军预防医学杂志,2017,35(6):571-574.
[4]黄国锋,谭清容,龙燕玲,等.匹伐他汀钙片治疗老年原发性高血压病合并高脂血症的疗效观察[J].华夏医学,2017,30(4):4-7.
[5]吴彦.阿托伐他汀对高血压患者颈动脉斑块的疗效观察[J].浙江临床医学,2016,18(8):1393-1395.
[6]刘金发,林杰.匹伐他汀钙联合依折麦布治疗冠心病合并高脂血症的疗效及安全性观察[J].解放军预防医学杂志,2018,36(9):1114-1117.
[7]温灵武,高伟青,刘菁,等.对比阿托伐他汀与瑞舒伐他汀在冠心病治疗中的应用价值[J].北方药学,2018,15(6):21-22.
[8]赵宏伟,孙磊,于倩,等.匹伐他汀和辛伐他汀治疗不稳定性心绞痛的效果及安全性比较[J].中国当代医药,2014,21(7):74-76.
[9]徐小明,罗兴迪,杨靓靓,等.阿托伐他汀钙片联合心血管药物治疗冠心病的临床研究[J].重庆医学,2016,45(19):2701-2702.
[10]李莉.瑞舒伐他汀与阿托伐他汀在冠心病调脂治疗中的药物经济学比较[J].海峡药学,2015,27(10):271-273.
[11]陈丽琴.分析不同他汀类药物(瑞舒伐他汀、阿托伐他汀)调脂效果及使用依从性[J].北方药学,2017,14(12):147-147.
[12]安素,张明.不同剂量普伐他汀对冠心病患者血脂与血清胱抑素C的影响及意义[J].海南医学院学报,2015,21(3):362-365.
[13]佀瑞淑.阿托伐他汀钙联合阿司匹林对冠心病患者血脂及炎性因子水平的影响[J].四川生理科学杂志,2018,40(2):109-111.
[14]周冠增.阿托伐他汀钙联合阿司匹林对冠心病患者血脂及炎性因子水平的影响[J].淮海医药,2018,36(3):350-352.
[15]于楠.氨氯地平联合阿托伐他汀钙片治疗高血压合并冠心病的效果观察[J].中国当代医药,2015,22(24):49-50,53.